Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
14.50    0.00 (0.00%)
Bid:
14.00
Ask:
15.00
Spread: 1.00 (7.143%)
Market Cap: £11.97m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Result of AGM

9 Dec 2022 16:08

RNS Number : 2744J
Frontier IP Group plc
09 December 2022
 

RNS

AIM: FIPP

9 December 2022

 

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Result of Annual General Meeting

 

Frontier IP (AIM: FIPP), a specialist in commercialising intellectual property, announces that at its annual general meeting, held earlier today, all resolutions were duly passed with the table below summarising proxy votes received.

 

 RESOLUTIONS

NO OF VOTES FOR

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

NO OF VOTES AGAINST

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

TOTAL VOTES CAST (EXCLUDING VOTES WITHHELD)

NO OF VOTES WITHHELD

ORDINARY

1) To receive the audited consolidated financial statements of the Company and its subsidiaries for the year ended 30 June 2022, together with the reports of the Directors and the Auditor thereon.

31,762,286

100.0%

0

0.0%

31,762,286

0

2) To approve the report of the Board to the members on directors' remuneration for the year ended 30 June 2022.

31,746,575

100.0%

4,800

0.0%

31,751,375

10,911

3) To re-appoint James M Fish as a Director of the Company, who retires by rotation and, being eligible, is offering himself for reappointment.

31,759,602

100.0%

0

0.0%

31,759,602

2,684

4) To re-appoint Campbell Wilson as a Director of the Company, who retires by rotation and, being eligible, is offering himself for reappointment.

31,759,602

100.0%

0

0.0%

31,759,602

2,684

5) To re-appoint BDO LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which financial statements are laid before shareholders.

31,757,658

100.0%

4,628

0.0%

31,762,286

0

6) To authorise the Directors to determine the auditor's remuneration.

31,759,602

100.0%

2,684

0.0%

31,762,286

0

7) To authorise the directors to allot shares.

28,377,302

89.3%

3,383,534

10.7%

31,760,836

1,450

8) To approve the Frontier IP Group plc Long Term Incentive Plan. 

28,371,240

89.4%

3,376,001

10.6%

31,747,241

15,045

SPECIAL

9) Authority to disapply pre-emption rights in connection with the allotment and issue of equity securities for cash in relation to (i) share option schemes; (ii) rights issue or similar offer; or (iii) allotment of equity securities up to 5% of the issued share capital.

28,365,452

89.3%

3,395,384

10.7%

31,760,836

1,450

10) Authority to disapply pre-emption rights to allot equity securities for cash.

31,745,351

99.95%

15,485

0.05%

31,760,836

1,450

11) Authority to purchase own shares on market.

27,193,531

99.97%

9,051

0.03%

27,202,582

4,559,704

 

 

Votes which have been cast at the discretion of the Chairman have been counted as votes for the resolutions. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution.

 

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications and Investor Relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGTLBFTMTMMBAT
Date   Source Headline
26th Jun 202610:03 amRNSHolding(s) in Company
25th Jun 20262:44 pmRNSHolding(s) in Company
25th Jun 20267:00 amRNSHolding(s) in Company
24th Jun 20267:00 amRNS-RPortfolio news: Investment in Fieldwork Robotics
23rd Jun 20267:00 amRNSPosting of Circular and Notice of General Meeting
19th Jun 20267:00 amRNSResult of Retail Offer
17th Jun 20267:00 amRNSResult of Placing and Subscription
16th Jun 20265:20 pmRNSRetail Offer
16th Jun 20264:58 pmRNSProposed Placing and Subscription
26th May 20267:00 amRNS-RPortfolio news: Dekiln strategic partnership
5th May 20267:00 amRNSAppointment of Chief Financial Officer
16th Apr 20264:07 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSPortfolio News: 2D Photonics subsidiary grant
13th Apr 20262:35 pmRNSHolding(s) in Company
10th Apr 202610:30 amRNSUpdate re Investee Company
8th Apr 20267:00 amRNS-RPortfolio news – Fieldwork Robotics £3M fundraise
31st Mar 20265:18 pmRNSHolding(s) in Company
30th Mar 20267:00 amRNSUnaudited Half Year Results
23rd Mar 20267:00 amRNS-RAlusid reaches milestone in European roll out
28th Jan 20264:28 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RPortfolio news - Strong results for TVG vaccine
12th Jan 202610:30 amRNSHolding(s) in Company
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 20251:00 pmRNSTotal Voting Rights
31st Dec 202512:30 pmRNSResult of AGM
31st Dec 202512:30 pmRNSResult of AGM
29th Dec 20252:37 pmRNSHolding(s) in Company
29th Dec 20252:37 pmRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20259:52 amRNSHolding(s) in Company
24th Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20252:17 pmRNSDirectors' Shareholdings
23rd Dec 20252:17 pmRNSDirectors’ Shareholdings
22nd Dec 20253:48 pmRNSResult of Retail Offer
22nd Dec 20253:48 pmRNSResult of Retail Offer
18th Dec 20259:15 amRNS-RDekiln benefits from £3 million funding
17th Dec 202511:54 amRNSResult of Placing and Subscription
17th Dec 20257:01 amRNSRetail Offer
17th Dec 20257:00 amRNSProposed Placing and Subscription to raise £870k
15th Dec 20257:00 amRNS-RPortfolio news- Alusid £500k pre-IPO funding round
10th Dec 20254:56 pmRNSHolding(s) in Company
9th Dec 20257:00 amRNSPosting of Annual Report & Notice of AGM
8th Dec 20257:00 amRNSFinal results for the year ended 30 June 2025
2nd Dec 20257:00 amRNS-RAlusid signs Swedish distribution agreement
6th Nov 20257:00 amRNSBord Change
3rd Nov 20257:00 amRNS-RTVG demonstrates success in animal trials
20th Oct 20257:00 amRNS-RAmprologix raises £740,000 in Pre-Series A round
25th Sep 20257:00 amRNSBoard Changes
24th Sep 20255:12 pmRNSHolding(s) in Company
13th Jun 20257:00 amRNSStrategic partnership for Cambridge innovation hub

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.